Caribou Biosciences, Inc. Insider Trading

CRBU

Last 12 months

Insiders sold 47K and bought nothing on the open market.

62% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2025.

Net open-market

−47K

0 buys · 5 sales

Under a 10b5-1 plan

62%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Mar 2025

Mar 14, 2025

Get an email when CRBU's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Feb 25	Timothy P Kelly Chief Technology Officer	SoldNo plan	6,228	$1.93	12K	7.8%	Form 4
Feb 24	Tina M. Albertson Chief Medical Officer	Sold10b5-1 plan	1,066	$1.96	2K	1.5%	Form 4
Feb 24	Ruhi Ahmad Khan Chief Business Officer	Sold10b5-1 plan	6,938	$1.96	14K	6.2%	Form 4
Feb 24	Timothy P Kelly Chief Technology Officer	SoldNo plan	3,147	$1.96	6K	3.8%	Form 4
Feb 24	Barbara G McClung Chief Legal Officer	Sold10b5-1 plan	6,938	$1.96	14K	1.4%	Form 4
Mar 14, 2025	Rachel E. Haurwitz President and CEO	Bought	20,000	$1.02	20K	0.5%	Form 4
Feb 21, 2025	Ruhi Ahmad Khan Chief Business Officer	Sold10b5-1 plan	3,564	$1.35	5K	5.1%	Form 4
Feb 21, 2025	Steven Kanner Chief Scientific Officer	Sold10b5-1 plan	3,564	$1.35	5K	0.8%	Form 4
Feb 21, 2025	Barbara G McClung Chief Legal Officer	Sold10b5-1 plan	3,564	$1.35	5K	0.8%	Form 4
Jan 29, 2025	Sriram Ryali Chief Financial Officer	Bought	17,360	$1.42	25K	New	Form 4

Feb 25No plan
Timothy P Kelly
Chief Technology Officer · sold 6,228 at $1.93
12K
7.8% of stake
Feb 2410b5-1 plan
Tina M. Albertson
Chief Medical Officer · sold 1,066 at $1.96
2K
1.5% of stake
Feb 2410b5-1 plan
Ruhi Ahmad Khan
Chief Business Officer · sold 6,938 at $1.96
14K
6.2% of stake
Feb 24No plan
Timothy P Kelly
Chief Technology Officer · sold 3,147 at $1.96
6K
3.8% of stake
Feb 2410b5-1 plan
Barbara G McClung
Chief Legal Officer · sold 6,938 at $1.96
14K
1.4% of stake
Mar 14, 2025
Rachel E. Haurwitz
President and CEO · bought 20,000 at $1.02
20K
0.5% of stake
Feb 21, 202510b5-1 plan
Ruhi Ahmad Khan
Chief Business Officer · sold 3,564 at $1.35
5K
5.1% of stake
Feb 21, 202510b5-1 plan
Steven Kanner
Chief Scientific Officer · sold 3,564 at $1.35
5K
0.8% of stake
Feb 21, 202510b5-1 plan
Barbara G McClung
Chief Legal Officer · sold 3,564 at $1.35
5K
0.8% of stake
Jan 29, 2025
Sriram Ryali
Chief Financial Officer · bought 17,360 at $1.42
25K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CRBU, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CRBU

CompareIntrinsic value

RLAYRelay Therapeutics Inc.

$18.03+3.38%40

XFORX4 Pharmaceuticals Inc.

$3.24+2.21%20

ELUTElutia Inc.

$0.76-6.52%20

SRZNSurrozen, Inc.

$31.65+5.08%10

TCRXTScan Therapeutics Inc.

$0.21+11.11%10

CRISCuris Inc.

$1.11+56.34%25

ZEOXZeo Scientifix Inc.

$0.97+0.00%25

CRSPCrispr Therapeutics AG

$51.78+3.57%40

Held by ETFs

CRBU is in 6 US ETFs. The largest of them, with CRBU's weight in each:

Spot a number that looks wrong? Check it in CRBU's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CRBU

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.